Tounjian Advisory Partners LLC Has $2.67 Million Holdings in Johnson & Johnson $JNJ

Tounjian Advisory Partners LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 26.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,898 shares of the company’s stock after selling 4,626 shares during the quarter. Johnson & Johnson comprises approximately 0.9% of Tounjian Advisory Partners LLC’s investment portfolio, making the stock its 25th largest position. Tounjian Advisory Partners LLC’s holdings in Johnson & Johnson were worth $2,669,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of JNJ. SOA Wealth Advisors LLC. boosted its position in Johnson & Johnson by 0.7% during the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock valued at $1,371,000 after acquiring an additional 53 shares during the last quarter. Ethos Financial Group LLC raised its position in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after acquiring an additional 53 shares in the last quarter. Pinnacle Holdings LLC raised its position in shares of Johnson & Johnson by 0.5% in the 3rd quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company’s stock worth $2,079,000 after acquiring an additional 54 shares in the last quarter. Bouchey Financial Group Ltd lifted its stake in shares of Johnson & Johnson by 0.8% in the 3rd quarter. Bouchey Financial Group Ltd now owns 7,249 shares of the company’s stock valued at $1,344,000 after purchasing an additional 54 shares during the period. Finally, Boltwood Capital Management boosted its position in shares of Johnson & Johnson by 1.3% during the 4th quarter. Boltwood Capital Management now owns 4,263 shares of the company’s stock valued at $882,000 after purchasing an additional 54 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.1%

Shares of NYSE:JNJ opened at $235.64 on Tuesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The business’s 50 day simple moving average is $235.73 and its two-hundred day simple moving average is $209.21. The firm has a market cap of $567.57 billion, a P/E ratio of 21.33, a PEG ratio of 2.32 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 30,142 shares of company stock worth $7,360,528 over the last ninety days. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on JNJ shares. Leerink Partners raised their target price on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research note on Thursday, January 22nd. Barclays increased their price target on Johnson & Johnson from $217.00 to $234.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Morgan Stanley set a $253.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, March 18th. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $236.91.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.